'Covaxin shows overall 78 pc interim efficacy, 100 pc efficacy against severe COVID-19 disease'
Apr 21, 2021
Hyderabad (Telangana) [India], April 21 : Covaxin, India's indigenous vaccine against COVID-19 demonstrated "overall interim clinical efficacy" of 78 per cent and 100 per cent efficacy against "severe COVID-19 disease" in Phase-III trials, informed Bharat Biotech and Indian Council of Medical Research (ICMR) on Wednesday.